Literature DB >> 27113603

Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinson's disease.

Yaqian Xu1, Jing Yang1, Xinyu Hu2, Huifang Shang3.   

Abstract

Brain gray matter volume (GMV) reduction has been reported in Parkinson's disease (PD) with mild cognitive impairment (PD-MCI) and in PD patients with dementia (PDD) with cumulative evidence using voxel-based morphometry (VBM). However, the findings of these studies have not been entirely concordant. Whole-brain VBM studies comparing PD-MCI with PD patients without cognitive impairment (PD-NCI) and comparing PDD with PD patients without dementia (PDND) were systematically searched in PubMed and EMBASE databases from January 1995 to December 2015. Coordinates with significant differences were extracted from each cluster. Meta-analysis was performed using AES-SDM to quantitatively evaluate the GMV changes. Five studies comparing 92 PD-MCI with 192 PD-NCI patients were included in the PD-MCI vs. PD-NCI meta-analysis. Ten studies with 168 PDD and 233 PDND patients were included in the PDD vs. PDND meta-analysis. Compared with PD-NCI, GMV reductions were observed in left superior temporal lobe, left insula and left superior frontal lobe in PD-MCI patients. Significant GMV reduction were found in bilateral superior temporal lobe extending to hippocampus, and left superior frontal lobe in PDD patients comparing with PDND. Meta-regression of PDD studies showed that disease duration was negatively correlated with GMV in the left superior frontal lobe. GMV reductions in the frontal-limbic-temporal regions were main features of cognitive decline in PD. Unilateral-to-bilateral development of GMV reduction in the frontal-limbic-temporal regions is a possible indicator for PD-MCI to PDD progression, whereas significant hippocampal GMV reduction may not be a marker for early cognitive decline in PD.

Entities:  

Keywords:  Gray matter volume; Meta-analysis; Parkinson’s disease dementia (PDD); Parkinson’s disease with mild cognitive impairment (PD-MCI); Signed differential mapping; Voxel-based morphometry

Mesh:

Year:  2016        PMID: 27113603     DOI: 10.1007/s00415-016-8122-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  51 in total

1.  Voxelwise meta-analysis of gray matter abnormalities in dementia with Lewy bodies.

Authors:  JianGuo Zhong; PingLei Pan; ZhenYu Dai; HaiCun Shi
Journal:  Eur J Radiol       Date:  2014-06-30       Impact factor: 3.528

2.  Cognitive impairments in advanced PD without dementia.

Authors:  J Green; W M McDonald; J L Vitek; M Evatt; A Freeman; M Haber; R A E Bakay; S Triche; B Sirockman; M R DeLong
Journal:  Neurology       Date:  2002-11-12       Impact factor: 9.910

3.  Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.

Authors:  P M Mattila; J O Rinne; H Helenius; D W Dickson; M Röyttä
Journal:  Acta Neuropathol       Date:  2000-09       Impact factor: 17.088

4.  Grey matter atrophy in cognitively impaired Parkinson's disease.

Authors:  Tracy R Melzer; Richard Watts; Michael R MacAskill; Toni L Pitcher; Leslie Livingston; Ross J Keenan; John C Dalrymple-Alford; Tim J Anderson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-09-02       Impact factor: 10.154

5.  Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects.

Authors:  Liana G Apostolova; Jonathan H Morra; Amity E Green; Kristy S Hwang; Christina Avedissian; Ellen Woo; Jeffrey L Cummings; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage       Date:  2010-01-18       Impact factor: 6.556

6.  Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia.

Authors:  Naroa Ibarretxe-Bilbao; Blanca Ramírez-Ruiz; Eduardo Tolosa; María Jose Martí; Francesc Valldeoriola; Nuria Bargalló; Carme Junqué
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

Review 7.  Functional imaging of cognition in Parkinson's disease.

Authors:  Maren Carbon; Rose-Marie Marié
Journal:  Curr Opin Neurol       Date:  2003-08       Impact factor: 5.710

8.  Progression of cortical thinning in early Parkinson's disease.

Authors:  Naroa Ibarretxe-Bilbao; Carme Junque; Barbara Segura; Hugo C Baggio; Maria J Marti; Francesc Valldeoriola; Nuria Bargallo; Eduardo Tolosa
Journal:  Mov Disord       Date:  2012-11-02       Impact factor: 10.338

9.  Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.

Authors:  Emma J Burton; Ian G McKeith; David J Burn; E David Williams; John T O'Brien
Journal:  Brain       Date:  2004-01-28       Impact factor: 13.501

10.  Changes of brain gray matter structure in Parkinson's disease patients with dementia.

Authors:  Jianguo Xia; Jinlin Miu; Hongbin Ding; Xiuping Wang; Hua Chen; Juan Wang; Juan Wu; Jingli Zhao; Huanxin Huang; Weizhong Tian
Journal:  Neural Regen Res       Date:  2013-05-15       Impact factor: 5.135

View more
  25 in total

1.  Joint Multi-modal Parcellation of the Human Striatum: Functions and Clinical Relevance.

Authors:  Xiaojin Liu; Simon B Eickhoff; Felix Hoffstaedter; Sarah Genon; Svenja Caspers; Kathrin Reetz; Imis Dogan; Claudia R Eickhoff; Ji Chen; Julian Caspers; Niels Reuter; Christian Mathys; André Aleman; Renaud Jardri; Valentin Riedl; Iris E Sommer; Kaustubh R Patil
Journal:  Neurosci Bull       Date:  2020-07-23       Impact factor: 5.203

2.  Do multiple system atrophy and Parkinson's disease show distinct patterns of volumetric alterations across hippocampal subfields? An exploratory study.

Authors:  Na Wang; Liang Zhang; HuaGuang Yang; XiaoGuang Luo; GuoGuang Fan
Journal:  Eur Radiol       Date:  2019-02-22       Impact factor: 5.315

3.  Olfactory impairment in Parkinson's disease is a consequence of central nervous system decline.

Authors:  Emilia Iannilli; Lars Stephan; Thomas Hummel; Heinz Reichmann; Antje Haehner
Journal:  J Neurol       Date:  2017-05-26       Impact factor: 4.849

4.  Gray matter microstructural alterations in manganese-exposed welders: a preliminary neuroimaging study.

Authors:  Jiayu Wu; Qiaoying Zhang; Pengfeng Sun; Hong Zhang; Ming Gao; Mingyue Ma; Yan Dong; Peng Liu; Xiaoping Wu
Journal:  Eur Radiol       Date:  2022-06-23       Impact factor: 5.315

5.  Independent effect of neurogenic orthostatic hypotension on mild cognitive impairment in Parkinson's disease.

Authors:  Sung Hoon Kang; Su Jin Chung; Jungyeun Lee; Seong-Beom Koh
Journal:  Clin Auton Res       Date:  2021-11-29       Impact factor: 4.435

Review 6.  Morphological basis of Parkinson disease-associated cognitive impairment: an update.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2022-06-20       Impact factor: 3.850

7.  The structural changes of gray matter in Parkinson disease patients with mild cognitive impairments.

Authors:  Lihua Li; Bingjun Ji; Ting Zhao; Xuan Cui; Jingtao Chen; Zhenyu Wang
Journal:  PLoS One       Date:  2022-07-20       Impact factor: 3.752

Review 8.  Gray matter asymmetries in aging and neurodegeneration: A review and meta-analysis.

Authors:  Lora Minkova; Annegret Habich; Jessica Peter; Christoph P Kaller; Simon B Eickhoff; Stefan Klöppel
Journal:  Hum Brain Mapp       Date:  2017-08-30       Impact factor: 5.038

9.  Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease.

Authors:  Erin K Donahue; Amjad Murdos; Michael W Jakowec; Nasim Sheikh-Bahaei; Arthur W Toga; Giselle M Petzinger; Farshid Sepehrband
Journal:  Mov Disord       Date:  2021-01-20       Impact factor: 10.338

10.  Subcortical Volumes Differ in Parkinson's Disease Motor Subtypes: New Insights into the Pathophysiology of Disparate Symptoms.

Authors:  Keren Rosenberg-Katz; Talia Herman; Yael Jacob; Efrat Kliper; Nir Giladi; Jeffery M Hausdorff
Journal:  Front Hum Neurosci       Date:  2016-07-11       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.